Recruiting Type 2 Diabetes Studies in Lebanon
About Type 2 Diabetes Clinical Trials in Lebanon
Type 2 diabetes is a chronic metabolic condition affecting over 37 million Americans, characterized by insulin resistance and progressive loss of beta-cell function. While metformin remains the first-line treatment, the treatment landscape has expanded dramatically with GLP-1 receptor agonists (semaglutide, tirzepatide), SGLT2 inhibitors (empagliflozin, dapagliflozin), and dual GIP/GLP-1 agonists showing both glycemic and cardiovascular benefits. Clinical trials are now exploring triple-hormone agonists, oral GLP-1 formulations, islet cell regeneration therapies, and precision medicine approaches that tailor treatment to individual metabolic profiles. Patients with uncontrolled HbA1c on current medications, those with diabetic complications, or newly diagnosed patients may qualify for enrollment.
There are currently 1 type 2 diabetes clinical trials recruiting participants in Lebanon, NH. These studies are seeking a combined 35 participants. Research is being sponsored by Dartmouth-Hitchcock Medical Center. Clinical trial participation is free and participants receive study-related medical care at no cost.
Type 2 Diabetes Clinical Trials in Lebanon — FAQ
Are there type 2 diabetes clinical trials in Lebanon?
Yes, there are 1 type 2 diabetes clinical trials currently recruiting in Lebanon, NH. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lebanon?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lebanon research site will contact you about next steps.
Are clinical trials in Lebanon free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lebanon studies also compensate for your time and travel.
What type 2 diabetes treatments are being tested?
The 1 active trials in Lebanon are testing new therapies including novel drugs, biologics, and treatment approaches for type 2 diabetes.
Data updated October 12, 2026 from ClinicalTrials.gov